Conamax

Conamax

Biotech

Information

The Conamax platform is a robustly fermentable engineered eukaryotic microbe capable of producing biopharmaceuticals with competitive cost and faster timeline. It is uniquely suited for making antibodies and promises to achieve productivity upward of 1 g/L/day. One of the most exciting features of this host organism is its ability to express glycoproteins harboring homogenous glycostructures which promote the desired immune cell functions. It is also advantaged by its ability to tolerate the engineering required to customize these glycostructures while preserving the microbe’s robustness.
ConagenConagen’s strain development, fermentation, and scale-up technologies deliver products which enhance the sales, production and profitability of our global partners across a broad spectrum of current and developing markets including pharmaceuticals. Our new proprietary microbial platform is enabled with faster, better and cheaper production of vaccines. Monoclonal antibodies and biopharmaceuticals for a wide range of therapeutic areas.

Log in